Plain-English translation of NCT04781140 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether a medication called SPN-812 (viloxazine extended-release) can safely and effectively treat ADHD symptoms in very young children ages 4 to 5. About half of the children in the study will receive the new medication, and half will receive a placebo (a pill that looks the same but has no active ingredient). The study will measure how well the medication helps with attention, impulse control, and behavior.
ADHD in young children is often challenging to treat, and there are limited treatment options available for preschoolers. This trial aims to see if this medication is a safe and effective option for this age group.
You likely qualify if…
You likely don't qualify if…
You would bring your child to the study clinic for screening visits over about 4 weeks to confirm they qualify. If your child is eligible, you would give them the study medication (or placebo) once daily for 6 weeks and attend follow-up visits where the study team asks questions about how your child is doing. The total time commitment is about 10 weeks from start to finish. Teachers or childcare providers may also be asked to report on your child's behavior at school or in group settings.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States